Trials / Completed
CompletedNCT01611480
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Moberg Pharma AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The aim is to evaluate efficacy and safety of three different dosing regimens of Limtop in a study involving 96 patients with actinic keratosis on the head or face.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod (topical use) |
Timeline
- Primary completion
- 2013-01-01
- First posted
- 2012-06-05
- Last updated
- 2013-06-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01611480. Inclusion in this directory is not an endorsement.